Candidemia in the cancer patient: diagnosis, treatment, and future directions

References

• Mantadakis E, Pana ZD, Zaoutis T. Candidemia in children: epidemiology, prevention and management. Mycoses. 2018.
   PubMed Web of Science ®Google Scholar
• Ulu Kilic A, Alp E, Cevahir F, et al. Epidemiology and cost implications of candidemia, a 6-year analysis from a developing country. Mycoses. 2017;60(3):198–203.
   PubMed Web of Science ®Google Scholar
• Aslani N, Janbabaei G, Abastabar M, et al. Identification of uncommon oral yeasts from cancer patients by MALDI-TOF mass spectrometry. BMC Infect Dis. 2018;18(1):24.
   PubMed Web of Science ®Google Scholar
• Li D, Xia R, Zhang Q, et al. Evaluation of candidemia in epidemiology and risk factors among cancer patients in a cancer center of China: an 8-year case-control study. BMC Infect Dis. 2017;17(1):536.
   PubMedGoogle Scholar
• McCarthy MW, Kalasauskas D, Petraitis V, et al. Fungal infections of the central nervous system in children. J Pediatric Infect Dis Soc. 2017;6(3):e123–e33.
   PubMed Web of Science ®Google Scholar
• McCarthy MW, Kontoyiannis DP, Cornely OA, et al. Novel agents and drug targets to meet the challenges of resistant fungi. J Infect Dis. 2017;216(suppl_3):S474–S83.
   PubMed Web of Science ®Google Scholar
• Viscoli C, Girmenia C, Marinus A, et al. Candidemia in cancer patients: a prospective, multicenter surveillance study by the invasive fungal infection group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC). Clin Infect Dis. 1999;28(5):1071–1079.
   PubMed Web of Science ®Google Scholar
• Okinaka K. Candidemia in cancer patients: focus mainly on hematological malignancyand hematopoietic stem cell transplantation. Med Mycol J. 2016;57(3):J117–23.
   PubMedGoogle Scholar
• McCarthy M, Walsh T. Emerging diagnostic and therapeutic options for treating mucormycosis. Expert Opinion on Orphan Drugs. 2016;1253–1261.
   Web of Science ®Google Scholar
• Buchan BW, Ledeboer NA. Advances in identification of clinical yeast isolates by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry. J Clin Microbiol. 2013;51(5):1359–1366.
   PubMed Web of Science ®Google Scholar
• Shinozaki M, Tochigi N, Sadamoto S, et al. Histopathological diagnosis of invasive fungal infections in formalin-fixed and paraffin-embedded tissues in conjunction with molecular methods. Med Mycol J. 2018;59(1):E7–E18.
   PubMedGoogle Scholar
• Machetti M, Viscoli C. Interactions and false positive results of galactomannan antigen detection for diagnosis of invasive aspergillosis. Infez Med. 2006;14(4):197–207.
   PubMedGoogle Scholar
• Jaijakul S, Vazquez JA, Swanson RN, et al. (1,3)-β-D-glucan as a prognostic marker of treatment response in invasive candidiasis. Clin Infect Dis. 2012;55(4):521–526.
   PubMed Web of Science ®Google Scholar
• Fukuda T, Boeckh M, Carter RA, et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood. 2003;102(3):827–833.
   PubMed Web of Science ®Google Scholar
• Zervou FN, Zacharioudakis IM, Kurpewski J, et al. T2 magnetic resonance for fungal diagnosis. Methods Mol Biol. 2017;1508:305–319.
   PubMedGoogle Scholar
• Hamula CL, Hughes K, Fisher BT, et al. T2Candida provides rapid and accurate species identification in pediatric cases of candidemia. Am J Clin Pathol. 2016;145(6):858–861.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Wolk DM, Lowery TJ. T2MR and T2Candida: novel technology for the rapid diagnosis of candidemia and invasive candidiasis. Future Microbiol. 2016;11(1):103–117.
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Pappas PG, Vazquez J, et al. Detecting infections rapidly and easily for candidemia trial, part 2 (DIRECT2): a prospective, multicenter study of the T2Candida panel. Clin Infect Dis. 2018;66(11):1678–1686.
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Nguyen MH. T2 magnetic resonance for the diagnosis of bloodstream infections: charting a path forward. J Antimicrob Chemother. 2018;73(suppl_4):iv2–iv5.
   PubMedGoogle Scholar
• Mery A, Sendid B, François N, et al. Application of mass spectrometry technology to the early diagnosis of invasive fungal infections. J Clin Microbiol. 2016.
   PubMed Web of Science ®Google Scholar
• Idelevich EA, Grünastel B, Becker K. rapid detection and identification of candidemia by direct blood culturing on solid medium by use of lysis-centrifugation method combined with matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS). J Clin Microbiol. 2017;55(1):97–100.
   PubMed Web of Science ®Google Scholar
• Kost K, Yi J, Rogers B, et al. Comparison of clinical methods for detecting carbapenem-resistant Enterobacteriaceae. Pract Lab Med. 2017;8:18–25.
   Google Scholar
• Lee HS, Shin JH, Choi MJ, et al. Comparison of the bruker biotyper and vitek ms matrix-assisted laser desorption/ionization time-of-flight mass spectrometry systems using a formic acid extraction method to identify common and uncommon yeast isolates. Ann Lab Med. 2017;37(3):223–230.
   PubMed Web of Science ®Google Scholar
• Chitasombat MN, Kontoyiannis DP. The ‘cephalosporin era’ of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections. Expert Opin Pharmacother. 2015;16(10):1543–1558.
   PubMed Web of Science ®Google Scholar
• Sevaille L, Gavara L, Bebrone C, et al. 1,2,4-Triazole-3-thione compounds as inhibitors of dizinc metallo-β-lactamases. ChemMedChem. 2017;12(12):972–985.
   PubMed Web of Science ®Google Scholar
• Rogers TE, Galgiani JN. Activity of fluconazole (UK 49,858) and ketoconazole against Candida albicans in vitro and in vivo. Antimicrob Agents Chemother. 1986;30(3):418–422.
   PubMed Web of Science ®Google Scholar
• Anderson TM, Clay MC, Cioffi AG, et al. Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat Chem Biol. 2014;10(5):400–406.
   PubMed Web of Science ®Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362(9390):1142–1151.
   PubMed Web of Science ®Google Scholar
• McCarthy MW, Walsh TJ. Drug development challenges and strategies to address emerging and resistant fungal pathogens. Expert Rev Anti Infect Ther. 2017;15(6):577–584.
   PubMed Web of Science ®Google Scholar
• Pfaller MA. Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. Am J Med. 2012;125(1 Suppl):S3–13.
   PubMed Web of Science ®Google Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Executive summary: clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):409–417.
   PubMedGoogle Scholar
• Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the infectious diseases society of America. Clin Infect Dis. 2016;62(4):e1–50.
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Rhomberg PR, et al. Activity of a long-acting echinocandin, CD101, determined using CLSI and EUCAST reference methods, against Candida and Aspergillus spp., including echinocandin- and azole-resistant isolates. J Antimicrob Chemother. 2016;71(10):2868–2873.
   PubMed Web of Science ®Google Scholar
• Chowdhary A, Sharma C, Meis JF. Candida auris: a rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog. 2017;13(5):e1006290.
   PubMed Web of Science ®Google Scholar
• Navalkele BD, Revankar S, Chandrasekar P. Candida auris: a worrisome, globally emerging pathogen. Expert Rev Anti Infect Ther. 2017.
   PubMed Web of Science ®Google Scholar
• Raad I, Hanna H, Boktour M, et al. Management of central venous catheters in patients with cancer and candidemia. Clin Infect Dis. 2004;38(8):1119–1127.
   PubMed Web of Science ®Google Scholar
• Viñuela-Sandoval L, Falces-Romero I, García-Rodríguez J, et al. Candidemia and colonization by Candida auris, a diagnostic challenge. Enferm Infecc Microbiol Clin. 2017;55:3193-3198.
   PubMed Web of Science ®Google Scholar
• Velasco E, Bigni R. A prospective cohort study evaluating the prognostic impact of clinical characteristics and comorbid conditions of hospitalized adult and pediatric cancer patients with candidemia. Eur J Clin Microbiol Infect Dis. 2008;27(11):1071–1078.
   PubMed Web of Science ®Google Scholar
• Uzun O, Ascioglu S, Anaissie EJ, et al. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis. 2001;32(12):1713–1717.
   PubMed Web of Science ®Google Scholar
• McCarthy MW, Walsh TJ. Prophylactic measures during induction for acute myeloid leukemia. Curr Oncol Rep. 2017;19(3):18.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Kontoyiannis DP. How to prophylax against invasive fungal infections in adult ALL? An unmet need. Mycoses. 2018;27:1045-1054.
   Web of Science ®Google Scholar
• Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007;25(34):5471–5489.
   PubMed Web of Science ®Google Scholar
• Vardakas KZ, Michalopoulos A, Falagas ME. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol. 2005;131(1):22–28.
   PubMed Web of Science ®Google Scholar
• MacMillan ML, Goodman JL, DeFor TE, et al. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med. 2002;112(5):369–379.
   PubMed Web of Science ®Google Scholar
• Wolff SN, Fay J, Stevens D, et al. Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American marrow transplant group. Bone Marrow Transplant. 2000;25(8):853–859.
   PubMed Web of Science ®Google Scholar
• Winston DJ, Chandrasekar PH, Lazarus HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Ann Intern Med. 1993;118(7):495–503.
   PubMed Web of Science ®Google Scholar
• Goodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med. 1992;326(13):845–851.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Mullane KM, Ostrosky-Zeichner L, et al. Isavuconazole for treatment of rare invasive fungal diseases. Mycoses. 2018;9:884-892.
   Web of Science ®Google Scholar
• Falces-Romero I, Quiles-Melero I, García-Rodríguez J. [In vitro susceptibility of cryptic species of Aspergillus fumigatus to isavuconazole, itraconazole and voriconazole by means of E-test]. Rev Iberoam Micol. 2018;31:1441-1449.
   PubMed Web of Science ®Google Scholar
• Fung M, Schwartz BS, Doernberg SB, et al. Breakthrough invasive fungal infections on isavuconazole prophylaxis and treatment: what is happening in the real-world setting? Clin Infect Dis. 2018.
   Web of Science ®Google Scholar
• McCarthy MW, Moriyama B, Petraitiene R, et al. Clinical pharmacokinetics and pharmacodynamics of isavuconazole. Clin Pharmacokinet. 2018.
   PubMedGoogle Scholar
• Perfect JR, Cornely OA, Heep M, et al. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: challenges and lessons of the VITAL trial. Mycoses. 2018;18:669-681.
   Web of Science ®Google Scholar
• Enoch DA, Yang H, Aliyu SH, et al. The changing epidemiology of invasive fungal infections. Methods Mol Biol. 2017;1508:17–65.
   PubMedGoogle Scholar
• Farmakiotis D, Kontoyiannis DP. Epidemiology of antifungal resistance in human pathogenic yeasts: current viewpoint and practical recommendations for management. Int J Antimicrob Agents. 2017;9:661-671.
   PubMed Web of Science ®Google Scholar
• Lockhart SR, Etienne KA, Vallabhaneni S, et al. Simultaneous emergence of multidrug-resistant candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses. Clin Infect Dis. 2017;64(2):134–140.
   PubMed Web of Science ®Google Scholar
• McCarthy M. Hospital transmitted Candida auris infections confirmed in the US. BMJ. 2016;355:i5978.
   PubMed Web of Science ®Google Scholar
• Abdolrasouli A, Armstrong-James D, Ryan L, et al. In vitro efficacy of disinfectants utilised for skin decolonisation and environmental decontamination during a hospital outbreak with Candida auris. Mycoses. 2017;27:555-566.
   PubMed Web of Science ®Google Scholar
• Al-Siyabi T, Al Busaidi I, Balkhair A, et al. First report of Candida auris in Oman: clinical and microbiological description of five candidemia cases. J Infect. 2017;75(4):373–376.
   PubMed Web of Science ®Google Scholar
• Araúz AB, Caceres DH, Santiago E, et al. Isolation of Candida auris from nine patients in Central America: importance of accurate diagnosis and susceptibility testing. Mycoses. 2017;29:772-781.
   PubMed Web of Science ®Google Scholar
• Kean R, Sherry L, Townsend E, et al. Surface disinfection challenges for Candida auris: an in-vitro study. J Hosp Infect. 2018;98(4):433–436.
   PubMed Web of Science ®Google Scholar
• De Bernardis F, Graziani S, Tirelli F, et al. Candida vaginitis: virulence, host response and vaccine prospects. Med Mycol. 2018;56(suppl_1):26–31.
   PubMedGoogle Scholar
• Pappas PG, Lionakis MS, Arendrup MC, et al. Invasive candidiasis. Nat Rev Dis Primers. 2018;4:18026.
   PubMed Web of Science ®Google Scholar
• Edwards JE, Schwartz MM, Schmidt CS, et al. A fungal immunotherapeutic vaccine (NDV-3A) for treatment of recurrent vulvovaginal candidiasis-a phase 2 randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2018;66(12):1928–1936.
   PubMed Web of Science ®Google Scholar
• Caño-Muñiz S, Anthony R, Niemann S, et al. New approaches and therapeutic options for mycobacterium tuberculosis in a Dormant state. Clin Microbiol Rev. 2018;31(1):3311-3322.
   PubMed Web of Science ®Google Scholar
• Chang CC, Slavin MA, Chen SC. New developments and directions in the clinical application of the echinocandins. Arch Toxicol. 2017.
   Web of Science ®Google Scholar
• Gonzalez-Lara MF, Sifuentes-Osornio J, Ostrosky-Zeichner L. Drugs in clinical development for fungal infections. Drugs. 2017.
   PubMed Web of Science ®Google Scholar
• James KD, Laudeman CP, Malkar NB, et al. Structure-activity relationships of a series of echinocandins and the discovery of CD101, a highly stable and soluble echinocandin with distinctive pharmacokinetic properties. Antimicrob Agents Chemother. 2017;61(2):2110-2121.
   Web of Science ®Google Scholar
• Ong V, Hough G, Schlosser M, et al. Preclinical evaluation of the stability, safety, and efficacy of CD101, a novel echinocandin. Antimicrob Agents Chemother. 2016;60(11):6872–6879.
   PubMed Web of Science ®Google Scholar
• Zhao Y, Perez WB, Jiménez-Ortigosa C, et al. CD101: a novel long-acting echinocandin. Cell Microbiol. 2016;18(9):1308–1316.
   PubMed Web of Science ®Google Scholar
• Denning DW, Bromley MJ. How to bolster the antifungal pipeline. Science. 2015;347(6229):1414–1416.
   PubMed Web of Science ®Google Scholar
• Berkow EL, Angulo D, Lockhart SR. In vitro activity of a novel glucan synthase inhibitor, SCY-078, against clinical isolates of Candida auris. Antimicrob Agents Chemother. 2017;61(7).
   Web of Science ®Google Scholar
• Lepak AJ, Marchillo K, Andes DR. Pharmacodynamic target evaluation of a novel oral glucan synthase inhibitor, SCY-078 (MK-3118), using an in vivo murine invasive candidiasis model. Antimicrob Agents Chemother. 2015;59(2):1265–1272.
   PubMed Web of Science ®Google Scholar
• Scorneaux B, Angulo D, Borroto-Esoda K, et al. SCY-078 Is fungicidal against candida species in time-kill studies. Antimicrob Agents Chemother. 2017;61(3).
   PubMed Web of Science ®Google Scholar
• McCarthy MW, Walsh TJ. Drugs currently under investigation for the treatment of invasive candidiasis. Expert Opin Investig Drugs. 2017;26(7):825–831.
   PubMed Web of Science ®Google Scholar
• McCarthy MW, Denning DW, Walsh TJ. future research priorities in fungal resistance. J Infect Dis. 2017;216(suppl_3):S484–S92.
   PubMed Web of Science ®Google Scholar